Effect of YM-53601, a novel squalene synthase inhibitor, on the clearance rate of plasma LDL and VLDL in hamsters

British Journal of Pharmacology

Volumn 137, Issue 4, 2002, Pages 561-567

  Ugawa, Tohru ^a   Kakuta, Hirotoshi ^a   Moritani, Hiroshi ^a   Inagaki, Osamu ^a  

^a ASTELLAS PHARMA INC   (Japan)

Author keywords

Cholesterol; Clearance rate; LDL; Non LDL receptor pathway; Squalene synthase; Triglyceride; VLDL; YM 53601

Indexed keywords

1,1' DIOCTADECYL 3,3,3',3' TETRAMETHYLINDOCARBOCYANINE; 2 [2 FLUORO 2 (QUINUCLIDIN 3 YLIDENE)ETHOXY] 9H CARBAZOLE; CLOFIBRATE; ER 28448; FENOFIBRATE; GEMFIBROZIL; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; LIPID EMULSION; LOW DENSITY LIPOPROTEIN; LOW DENSITY LIPOPROTEIN RECEPTOR; POTASSIUM BROMIDE; PROBUCOL; PROTAMINE SULFATE; SODIUM AZIDE; SQUALENE SYNTHASE INHIBITOR; UNCLASSIFIED DRUG; VERY LOW DENSITY LIPOPROTEIN; YM 53601; ZARAGOZIC ACID A; ENZYME INHIBITOR; LOW DENSITY LIPOPROTEIN CHOLESTEROL; QUINUCLIDINE DERIVATIVE; SQUALENE SYNTHASE; VERY LOW DENSITY LIPOPROTEIN CHOLESTEROL;

ANIMAL EXPERIMENT; ARTICLE; CHOLESTEROL BLOOD LEVEL; CHOLESTEROL METABOLISM; CLEARANCE; CONTROLLED STUDY; DRUG MECHANISM; HAMSTER; HYPERTRIGLYCERIDEMIA; MALE; NONHUMAN; PRIORITY JOURNAL; RECEPTOR BINDING; TRIACYLGLYCEROL BLOOD LEVEL; ANIMAL; BLOOD; DRUG ANTAGONISM; DRUG EFFECT; METABOLIC CLEARANCE RATE; METABOLISM; PHYSIOLOGY; SYRIAN HAMSTER;

ANIMALS; CHOLESTEROL, LDL; CHOLESTEROL, VLDL; CRICETINAE; ENZYME INHIBITORS; FARNESYL-DIPHOSPHATE FARNESYLTRANSFERASE; MALE; MESOCRICETUS; METABOLIC CLEARANCE RATE; QUINUCLIDINES;

EID: 0036800653     PISSN: 00071188     EISSN: None     Source Type: Journal    
DOI: 10.1038/sj.bjp.0704906     Document Type: Article

References (24)

1. Amin, D., Rutledge, R.Z., Needle, S.N., Galczenski, H.F., Neuenschwander, K., Scotese, A.C., Maguire, M.P., Bush, R.C., Hele, D.J., Bilder, G.E. & Perrone, M.H. (1997). RPR 107393, a potent squalene synthase inhibitor and orally effective cholesterol-lowering agent: Comparison with inhibitors of HMG-CoA reductase. J. Pharmacol. Exp. Ther., 281, 746-752.
2. Arakawa, R., Tanaka, T., Sakamoto, Y., Kasai, H., Nagayama, T. & Saitoh, K. (1995). Hypolipidemic mechanisms of fenofibrate (1) lipid efflux from the circulation in rats. Jpn. Pharmacol. Ther., 23, S1055-S1061.
3. Brown, M.S. & Goldstein, J.L. (1997). The SREBP pathway: Regulation of cholesterol metabolism by proteolysis of a membrane-bound transcription factor. Cell, 89, 331-340.
4. Carlson, L.A. & Hallberg, D. (1963). Studies on the elimination of exogenous lipids from the blood stream. The kinetics of the elimination of a fat emulsion and of chylomicrons in the dog after a single injection. Act. Physiol. Scand. 59, 52-61.
5. Chappell, D.A. & Medh, J.D. (1998). Receptor-mediated mechanisms of lipoprotein remnant catabolism. Prog. Lipid Res., 37. 393-422.
6. Cullen, P. (2000). Evidence that triglycerides are an independent coronary heart disease risk factor. Am. J. Cardiol., 86, 943-949.
7. Gofman, J.W., Lindgren, F.T. & Elliott, H. (1949). Ultracentrifugal studies of lipoproteins of human serum. J. Biol. Chem., 179, 973-979.
8. Habeeb, A.F. (1966). Determination of free amino groups in proteins by trinitrobenzenesulfonic acid. Anal. Biochem., 14, 328-336.
9. Hiyoshi, H., Yanagimachi, M., Ito, M., Saeki, T., Yoshida, I., Okada, T., Ikuta, H., Shinmyo, D., Tanaka, K., Kurusu, N. & Tanaka, H. (2001). Squalene synthase inhibitors reduce plasma triglyceride through a low-density lipoprotein receptorindependent mechanism. Eur. J. Pharmacol., 431, 345-352.
10. Hultin, M., Carneheim, C., Rosenqvist, K. & Olivecrona, T. (1995). Intravenous lipid emulsions: Removal mechanisms as compared to chylomicrons. J. Lipid. Res., 36, 2174-2184.
11. Innerarity, T.L., Pitas, R.E. & Mahley, R.W. (1986). Lipoprotein-receptor interactions. Methods Enzymol., 129, 542-565.
12. Kesaniemi, Y.A. Beltz, W.F. & Grundy, S.M. (1985). Comparison of clofibrate and caloric restriction on kinetics of very low density lipoproteins triglyceride. Arteriosclerosis, 5, 153-161.
13. Kesaniemi, Y.A. & Grundy, S.M. (1984). Influence of gemfibrozil and clofibrate on metabolism of cholesterol and plasma triglyceride in man. JAMA, 251, 2241-2246.
14. Lowry, O.H., Rosebrough, N.J., Farr, A.L. & Randall, R.J. (1951). Protein measurement with the Folin phenol reagent. J. Biol. Chem., 193, 265-275.
15. Naruszewicz, M., Carew, T.E., Pittman, R.C., Witztum, J.L. & Steinberg, D. (1984). A novel mechanism by which probucol lowers low density lipoprotein levels demonstrated in the LDL receptor-deficient rabbit. J. Lipid Res., 25, 1206-1213.
16. Ness, G.C., Zhao, Z. & Keller, K. (1994). Effect of squalene synthase inhibition on the expression of hepatic cholesterol biosynthetic enzymes, LDL receptor, and cholesterol 7alpha hydroxylase. Arch. Biochem. Biophys., 311, 277-285.
17. Ness, G.C., Zhao, Z. & Lopez, D. (1996). Inhibitors of cholesterol biosynthesis increase hepatic low-density lipoprotein receptor protein degradation. Arch. Biochem. Biophys., 325, 242-248.
18. Slater, H.R., Mckinney, L., Packard C.J. & Shepherd, J. (1984). Contribution of the receptor pathway to low density lipoprotein catabolism in humans. Arteriosclerosis, 4, 604-613.
19. Spady, D.K., Bilheimer, D.W. & Dietschy, J.M. (1983). Rates of receptor-dependent and -independent low density lipoprotein uptake in the hamster. Proc. Natl. Acad. Sci. U.S.A., 80, 3499-3503.
20. Suzuki, H., Yamazaki, H., Aoki, T., Kojima, J., Tamaki, T., Sato, F., Kitahara, M. & Saito, Y. (2000). Lipid-lowering and antiatherosclerotic effect of NK-104, a potent 3-hydroxy-3-methylglutaryl coeznyme A reductase inhibitor, in Watanabe heritable hyperlipidemic rabbits. Arzneim.-Forsch./Drug Res., 50, 995-1003.
21. Tsutsumi, K., Inoue, Y., Shima, A., Iwasaki, K., Kawamura M. & Murase, T. (1993). The novel compound NI-1886 increases lipoprotein lipase activity with resulting elevation of high density lipoprotein cholesterol, and long-term administration inhibits atherogenesis in the coronary artery of rats with experimental atherosclerosis. J. Clin. Invest., 92, 411-417.
22. Ugawa, T., Kakuta, H., Moritani, H., Matsuda, K., Ishihara, T., Yamaguchi, M., Naganuma, S., Iizumi, Y. & Shikama, H. (2000). YM-53601, a novel squalene synthease inhibitor, reduces plasma cholesterol and triglyceride levels in several animal species. Br. J. Pharmacol., 131, 63-70.
23. Wada, S., Koizumi, M., Sasahara, K., Neichi, T., Nakakimura, H., Onoda, F. & Hata, S. (1981). The lipid-lowering profile in rodents. Atherosclerosis, 40, 263-271.
24. Weisgraber, K.H., Innerarity, T.L. & Mahley, R.W. (1978). Role of lysine residues of plasma lipoproteins in high affinity binding to cell surface receptors on human fibroblasts. J. Biol. Chem., 253, 9053-9062.